Presentation of final positive phase 1b/II clinical trial results for sabizabulin in metastatic castration resistant prostate cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Veru Inc. announced that the final results from the Phase 1b/II clinical study of sabizabulin, a novel oral cytoskeleton disruptor, in 80 men with metastatic castration resistant prostate cancer (mCRPC) that progressed after receiving at least one androgen receptor targeting agent was presented at a poster session during the 2022 American Society of Clinical Oncology Annual Meeting which is being held June 3-7, 2022.
Highlights of final results from the Phase 1b/II clinical study are as follows>: Safety ;- Sabizabulin 63mg oral daily dosing was well tolerated with no clinically significant reports of neurotoxicity or neutropenia. Efficacy ; Sabizabulin administration resulted in both cytotoxic and cytostatic anticancer activity with PSA declines and objective and durable tumor responses. For patients with measurable disease, the objective response rate was 20.7%, and for all patients who received at least the 63mg dose, the median radiographic progression free survival was 11.4 months.
Furthermore, the full study has been published online ahead of print as Mark Markowski et al." A Phase Ib/II study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration resistant prostate cancer with progression on an androgen receptor targeting agent ". Clinical Cancer Research 2022 (doi:10.1158/1078-0432.CCR-22-0162).
The Phase III VERACITY clinical study of men with metastatic castration resistant prostate cancer that has progressed on at least one androgen receptor targeting agent compared with the active control is enrolling with the anticipated completion of enrollment at the end of calendar 2022.
Related news and insights
Palisade Bio, Inc. announced the first patient has been dosed in its Phase III study evaluating LB 1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.
bluebird bio, Inc. announced the FDA has approved Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
Edwards Lifesciences Corporation announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR).